LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Crizotinib | 0.04 | uM | LJP5 | 3 | A24 | 72 | hr | 868 | 2323 | 3440 | 0.6752 | 0.6413 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 868 | 2709 | 3286 | 0.8243 | 0.8086 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 868 | 2839 | 3505 | 0.8099 | 0.8012 |
MDA-MB-231 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 868 | 2789 | 3440 | 0.8107 | 0.7995 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 868 | 2318 | 3286 | 0.7054 | 0.6676 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 868 | 2372 | 3505 | 0.6767 | 0.6474 |
MDA-MB-231 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 868 | 2510 | 3440 | 0.7296 | 0.7065 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 868 | 1818 | 3286 | 0.5532 | 0.4694 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 868 | 1804 | 3505 | 0.5146 | 0.4380 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 868 | 1743 | 3440 | 0.5066 | 0.4203 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 868 | 1116 | 3286 | 0.3396 | 0.1397 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 868 | 1099 | 3505 | 0.3135 | 0.1243 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 868 | 1185 | 3440 | 0.3445 | 0.1696 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 1 | A19 | 72 | hr | 868 | 1079 | 3286 | 0.3283 | 0.1199 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 2 | A19 | 72 | hr | 868 | 1097 | 3505 | 0.3129 | 0.1232 |
MDA-MB-231 | Crizotinib | 10 | uM | LJP5 | 3 | A19 | 72 | hr | 868 | 1084 | 3440 | 0.3151 | 0.1183 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 1 | D06 | 72 | hr | 868 | 3747 | 3429 | 1.0925 | 1.0913 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 2 | D06 | 72 | hr | 868 | 3445 | 3652 | 0.9433 | 0.9445 |
MDA-MB-231 | BMS345541 | 0.04 | uM | LJP6 | 3 | D06 | 72 | hr | 868 | 3471 | 3587 | 0.9676 | 0.9681 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 1 | D05 | 72 | hr | 868 | 4085 | 3429 | 1.1910 | 1.1844 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 2 | D05 | 72 | hr | 868 | 3550 | 3652 | 0.9721 | 0.9729 |
MDA-MB-231 | BMS345541 | 0.12 | uM | LJP6 | 3 | D05 | 72 | hr | 868 | 3366 | 3587 | 0.9383 | 0.9388 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 1 | D04 | 72 | hr | 868 | 3443 | 3429 | 1.0039 | 1.0039 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 2 | D04 | 72 | hr | 868 | 3191 | 3652 | 0.8738 | 0.8739 |
MDA-MB-231 | BMS345541 | 0.37 | uM | LJP6 | 3 | D04 | 72 | hr | 868 | 3152 | 3587 | 0.8787 | 0.8775 |